Study Purpose and Population Epidemiology of rare diseases is important for clinicians to consider, as prevalence and incidence inform the healthcare community about likelihood of disease within an at-risk population. Studies in epidemiology also help to support...
Clinically eligible lives data powered by STATinMED RWD Insights offer accurate and timely TRUE market opportunity, where detailed utilization management policies are managed, and contracts are negotiated.
Rare diseases are not so rare in RWD. Accounting for variability in access to care based on payer and healthcare infrastructure, our claims data population in STATinMED RWD Insights can help to monitor the outcomes for those with rare diseases and identify gaps in available therapeutics and healthcare resources.
Through real-world evidence (RWE), prescriptions reveal the process and delivery of healthcare. A prescription for a diagnostic test or medication reflects medical practice patterns, healthcare systems, and payer reimbursement for services.
With STATinMED RWD Insights we have the power to examine more than 80% of the US healthcare system’s all-payer medical and pharmacy claims, with patient-level data across all-provider types to support a variety of evidence generation needs.